Lola Maksumova M.D., Ph.D. is a well documented scientist at the Departments of Pediatrics, Microbiology and Immunology, and Pathology and Laboratory Medicine, University of British Columbia. She is the Chief Operating officer and Senior Vice President at Kedem & I think that she may be able to turn this stock around. I have read her work & I believe that she sees the potential in this stock or she wouldn't be in this position. I don't understand why Dr. Salari resigned, but Kedem still has the patients on the sublinguals & Dr. Salari still holds much of the stock in the company. Perhaps we need to convince Pfizer to take an interest in this technology, which could make money for them and us.
